• Explore /
  • Poster
  • / Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: A randomized phase Ib study and the evolution of the functionality of microbial communities with treatment.

Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: A randomized phase Ib study and the evolution of the functionality of microbial communities with treatment.

Abstract Poster

Authors

Nazli Dizman

Nazli Dizman

City of Hope Comprehensive Cancer Center, Duarte, CA

Nazli Dizman , Luis A Meza , Paulo Gustavo Bergerot , Marice Alcantara , Tanya B. Dorff , Yung Lyou , Paul Henry Frankel , Marian Llamas , Joann Hsu , Zeynep Busra Zengin , Jasnoor Malhotra , John D Gillece , Lauren J Reining , Jeffrey M. Trent , Motomichi Takahashi , Kentaro Oka , Seiya Higashi , Sarah K Highlander , Sumanta K. Pal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Translational Research, Tumor Biology, Biomarkers, and Pathology

Clinical Trial Registration Number

NCT03829111

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 371)

DOI

10.1200/JCO.2022.40.6_suppl.371

Abstract #

371

Poster Bd #

L6

Abstract Disclosures

Similar Posters

First Author: Hedyeh Ebrahimi

First Author: Yu-Wei Chen

First Author: Yu-Wei Chen

First Author: Luis A Meza